| Literature DB >> 29588472 |
G Büchele1, K P Günther2, H Brenner3,4, W Puhl5, T Stürmer6, D Rothenbacher7, R E Brenner8.
Abstract
Osteoarthritis (OA) is a common musculoskeletal disorder and occur in different patterns. However, its impact on long-term all-cause-mortality is inconclusive. STUDY AIMS: Investigate 20-year all-cause-mortality in patients with hip/knee arthroplasty (recruited 1995/1996, N = 809) from the Ulm Osteoarthritis Study-cohort, in comparison to general population. Furthermore, to enlighten the triangle between baseline life-style and cardio-metabolic risk factors, phenotypic OA-patterns (laterality, generalization, cause) and all-cause-mortality. Mortality was assessed during 20 years follow-up. Standardized mortality ratios (SMR), adjusted odds ratios and hazard ratios (aHR) were calculated. After five years cohort-mortality was reduced compared to the general population, however 20 years later assimilated (SMR = 1.11; 95%-CI 0.73-1.49). OA-patterns were associated with age, cholesterol, and overweight/obesity. In comparison to primary OA decreased mortality was observed for patients with secondary OA (aHR = 0.76; 95%-CI 0.61-0.95) adjusted for age, smoking, overweight/obesity, diabetes, hypertension, cardiac insufficiency, uric acid, and lower cholesterol. There was no increased mortality in patients after 20 years follow-up compared to general population. Significantly decreased mortality in secondary compared to primary OA suggests a subtype-specific involvement of systemic co-factors in determination of all-cause-mortality. Because cardio-metabolic risk factors were associated with increased risk of bilateral OA and lower long-term survival, those risk factors should be consequently targeted in OA-patients.Entities:
Mesh:
Year: 2018 PMID: 29588472 PMCID: PMC5869736 DOI: 10.1038/s41598-018-23573-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Patients flow chart and mortality during 20 years of follow-up. OA osteoarthritis, N number of patients.
Patient characteristics at baseline.
| (N, % of total cohort) | Total | Hip | Knee | |||
|---|---|---|---|---|---|---|
| Total cohort | 809 | (100.0%) | 420 | (51.92%) | 389 | 48.08%) |
| Sex female | 504 | (62.3%) | 221 | (52.6%) | 283 | (72.8%) |
| Age (years; N = 809; Median, Q1-Q3) | 65 | (58–70) | 62 | (55–68) | 67 | (63–71) |
| 25–<60 y | 236 | (29.2%) | 182 | (43.3%) | 54 | (13.9%) |
| 60–<70 y | 351 | (43.4%) | 153 | (36.4%) | 198 | (50.9%) |
| 70–75 y | 222 | (27.4%) | 85 | (20.2%) | 137 | (35.2%) |
| Smoking: Former smoker | 238 | (29.4%) | 141 | (33.6%) | 97 | (24.9%) |
| Current smoker | 102 | (12.6%) | 70 | (16.7%) | 32 | (8.2%) |
| BMI (kg/m²; N = 809; Median, Q1-Q3) | 27.9 | (25.5–30.9) | 26.8 | (24.5–29.5) | 29.2 | (26.5–32.1) |
| <25 kg/m² | 181 | (22.4%) | 126 | (30.0%) | 55 | (14.1%) |
| 25–<30 kg/m² | 375 | (46.4%) | 200 | (47.6%) | 175 | (45.0%) |
| 30–<35 kg/m² | 200 | (24.7%) | 76 | (18.1%) | 124 | (31.9%) |
| >=35 kg/m² | 53 | (6.6%) | 18 | (4.3%) | 35 | (9.0%) |
| History of overweight/obesity | 466 | (57.6%) | 191 | (45.5%) | 275 | (70.7%) |
| Diabetes mellitus type 2 | 70 | (8.7%) | 28 | (6.7%) | 42 | (10.8%) |
| Gout | 100 | (12.4%) | 43 | (10.2%) | 57 | (14.7%) |
| Hypertension | 415 | (51.3%) | 190 | (45.2%) | 225 | (57.8%) |
| Cardiac infarction | 34 | (4.2%) | 18 | (4.3%) | 16 | (4.1%) |
| Cardiac insufficiency | 153 | (18.9%) | 57 | (13.6%) | 96 | (24.7%) |
| Hypercholesterolemia | 259 | (32.0%) | 127 | (30.2%) | 132 | (33.9%) |
| Unknown | 123 | (15.2%) | 64 | (15.2%) | 59 | (15.2%) |
| Cholesterol (mmol/l; N = 683; Median, Q1-Q3) | 5.7 | (5.1–6.4) | 5.6 | (5.0–6.3) | 5.8 | (5.2–6.4) |
| Uric acid (mmol/l; N = 699; Median, Q1-Q3) | 315.4 | (265.0–376.0) | 315.4 | (267.8–376.0) | 313.5 | (257.5–375.5) |
| hs-CRP (mg/l; N = 770; Median, Q1-Q3) | 2.52 | (1.22–4.97) | 2.59 | (1.19–4.96) | 2.47 | (1.26–5.00) |
| Bilateral OA | 622 | (76.9%) | 330 | (78.6%) | 292 | (75.1%) |
| Unilateral OA | 114 | (14.1%) | 72 | (17.1%) | 42 | (10.8%) |
| Unknown | 73 | (9.0%) | 18 | (4.3%) | 55 | (14.1%) |
| Generalized OA | 171 | (21.1%) | 64 | (15.2%) | 107 | (27.5%) |
| Not-generalized OA | 468 | (57.8%) | 268 | (63.8%) | 200 | (51.4%) |
| Unknown | 170 | (21.0%) | 88 | (21.0%) | 82 | (21.1%) |
| Secondary OA | 296 | (36.6%) | 170 | (40.5%) | 126 | (32.4%) |
| Primary OA | 489 | (60.4%) | 238 | (56.7%) | 251 | (64.5%) |
| Unknown | 24 | (3.0%) | 12 | (2.9%) | 12 | (3.1%) |
|
| ||||||
| Deceased (N,%) | 407 | (50.3%) | 170 | (40.5%) | 237 | (60.9%) |
| Observation time (years; Median, Q1-Q3) | 18.4 | (11.4–19.2) | 18.6 | (12.3–19.3) | 16.7 | (11.1–19.1) |
N number of patients; Q1 first quartile; Q3 third quartile.
Figure 2Age-specific mortality in 5-year periods after arthroplasty in the study cohort () (baseline recruitment Jan. 1995 until Dec. 1996) and general population (). SMR standardized mortality ratio.
Survival time analyses.
| Model 1& | Model 2* | |||||
|---|---|---|---|---|---|---|
| aHR | 95% CI | p-value | aHR | 95% CI | p-value | |
| Age (years; per SD) |
|
| < |
|
| < |
| Smoking (former vs. non-smoker) | 0.96 | (0.75–1.22) | 0.72 | 0.95 | (0.74–1.22) | 0.70 |
| Smoking (current vs. non-smoker) |
|
|
|
|
|
|
| Localization (hip vs. knee) |
|
|
| |||
| BMI (kg/m²; per SD) | 1.06 | (0.96–1.17) | 0.25 |
| ||
| BMI (25–30 vs <25) | 0.97 | (0.74–1.26) | 0.81 |
| ||
| BMI (30–35 vs. <25) | 1.16 | (0.87–1.54) | 0.32 |
| ||
| BMI (>35 vs. <25) | 1.22 | (0.80–1.86) | 0.36 |
| ||
| History of overweight/obesity (yes vs. no) |
|
|
|
|
|
|
| Diabetes mellitus type 2 (yes vs. no) |
|
|
|
|
|
|
| Gout (yes vs. no) |
|
|
| |||
| Hypertension (yes vs. no) |
|
|
|
|
|
|
| Cardiac infarction (yes vs. no) | 1.40 | (0.92–2.12) | 0.11 | |||
| Cardiac insufficiency (yes vs. no) |
|
|
|
|
|
|
| Hypercholesterolemia (reference: no) | ||||||
| Hypercholesterolemia yes | 0.91 | (0.73–1.13) | 0.38 |
| ||
| Unknown | 1.00 | (0.75–1.33) | 0.99 |
| ||
| Cholesterol (mmol/l; per SD) | 0.91 | (0.81–1.02) | 0.10 |
|
|
|
| Uric acid (mmol/l; per SD) |
|
|
|
|
|
|
| hs-CRP (log mg/l; per SD) | 1.08 | (0.97–1.19) | 0.16 | |||
| Laterality of OA (reference: unilateral) | ||||||
| Bilateral OA |
|
|
| 1.28 | (0.89–1.82) | 0.18 |
| Unknown |
|
|
|
|
|
|
| Generalization of OA (reference: not generalized) | ||||||
| Generalized OA | 1.15 | (0.91–1.46) | 0.24 | |||
| Unknown | 1.17 | (0.91–1.52) | 0.22 | |||
| Secondary OA (reference: primary) | ||||||
| Secondary OA |
|
|
|
|
|
|
| Unknown |
|
|
| 1.36 | (0.77–2.41) | 0.29 |
aHR adjusted Hazard Ratios; CI confidence intervals; SD standard deviation for age 8.75 years, for BMI 4.28 kg/m2, for cholesterol 1.09 mmol/l, for uric acid 84.24 mmol/l, for CRP 1.06 log mg/l; OA osteoarthritis All models are statistically controlled for sex. Bold marked associations revealed p-values below 0.10. &Model 1 shows hazard ratios with 95% confidence intervals adjusted for age, smoking status, and localization. *Model 2 shows all significant mutually adjusted hazard ratios with 95% confidence intervals after backward selection performed “by hand”. Variables not included in model 2 due to high overlap with other variables. In the final model, only variables with p-values less than 0.10 in at least one substratum were kept.
Figure 3Adjusted survival probabilities stratified for sex. Estimated in Model 2 and adjusted for age, current smoking, self-reported history of overweight/obesity, diabetes, hypertension, cardiac insufficiency, uric acid, cholesterol, and laterality and secondary or primary cause of OA.